[PDF] Top 20 Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)

... GIST cells or excess tissue from patients (snap frozen) were lysed in NP-40 lysis buffer containing 50 mM Tris.HCl (pH 7.4), 0.15 M NaCl, 0.5% NP- 40, 1 mM DTT, 50 mM Sodium Fluoride, and 2 µl/ml Protease ... See full document

... previously, tumors exposed to imatinib develop secondary mutations that confer ...removing resistant clones, removing as much stable or responding disease as is feasible to minimize the development ... See full document

... two novel TKI inhibitors, nilotinib and regorafenib, have been shown to be promising in the control of both imatinib- resistant and sunitinib-resistant ...in imatinib-resistant ... See full document

... Abstract: Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical ...the tyrosine kinase ... See full document

... describe tumors lacking smooth muscle differentiation or immunohistochemical features of Schwann cells ...the gastrointestinal pacemaker cell ...the gastrointestinal tract, anywhere from the foregut ... See full document

... their combination, serve the purpose of reducing tumor burden to the greatest extent, leaving no visible tumor cell to develop resistance during subsequent TKI ...localized GIST, for whom optimal duration ... See full document

... with imatinib. Our patient has been treated with imatinib for 24 ...for tyrosine kinase inhibitors in the treat- ment of extra-abdominal desmoid tumors despite a lim- ited role for ... See full document

... with GIST treated with surgery from 1996 to ...the gastrointestinal tract while the remainder (n = 261) had extra-intestinal ...with gastrointestinal tract tumor compared with 105 months for patients ... See full document

... Surgery remains the primary treatment for resectable GIST and offers the only chance of cure. However, IM has an important role to play in patients with increased risk of recur- rence. Integration of IM with the ... See full document

... protein tyrosine kinases: the intracellular ABL kinase, the chimeric BCR-ABL fusion oncoprotein of chronic myeloid leukemia, the trans-membrane receptor KIT, and the platelet-derived growth factor ... See full document

... the imatinib arm compared to 83% in the placebo ...of imatinib following complete resection of ...high-risk GIST, based on size criteria and mitotic index as defined by Fletcher and colleagues, ... See full document

... of imatinib based on the genotype of the GIST ...ceiving imatinib, activating mutations in KIT and PDGFRA were found in 88 and ...were imatinib- ...of imatinib [22]. Patients whose ... See full document

... for GIST. However, anticancer drugs, especially imatinib is dramatically im- ...portant. Imatinib is a selective tyrosine kinase inhibitor of c-kit and PDGFRA, and represents a new ... See full document

... upper gastrointestinal endoscopy, during which a smooth submucosal tumor with a ‘delle’ was noted on the poste- rior wall of the gastric angle (Figure 1A, ...Although GIST was strongly suspected on the ... See full document

... necessary. GIST lesions exhibit a fragile pseudo capsule, so the intraop-procedure must be optimized to minimize the risk of tumour rupture which could increase the risk of peritoneal ...2012). Imatinib (a ... See full document

... with imatinib treatment in chronic phase CML patients resistant or intolerant to interferon- α further emphasized its exceptional potency (Kantarjian et al 2002a, b; Cervantes et al 2003; Kantarjian et al ... See full document

... Between 1987 and 2004, 25 patients (15 male and 10 female, mean age of 69 ± 8 years, range 34–80) underwent surgical resection for different type of GIST. The tumors were located in the stomach, small ... See full document

... sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Correlation of computed tomography and 392[r] ... See full document

... the gastrointestinal tumors, which re- veals a conspicuous discrepancy between the two ...two tumors is still ...of tumors of differ- ent origins in the same organ, such as the gene mutation ... See full document

... mg/day) imatinib analogous to that recommended in the advanced ...adjuvant imatinib over one year but should the treatment duration be longer? We know from the BFR-14 trial in patients with advanced ... See full document